Posts by John

Bayer joins forces with UCHealth, Children’s Hospital Colorado, and CU Anschutz to launch innovative clinical trials and accelerate medical breakthroughs.

Over $1.4 billion is flooding into AI-driven cardiovascular drug development. Discover how machine learning is accelerating heart disease therapy discovery.

Surgeons have successfully used teleoperated humanoid robots in live pre-clinical trials, marking a major leap forward for robotic-assisted surgery.

New research suggests guanfacine and N-acetylcysteine may help alleviate chronic fatigue and brain fog in Long COVID patients. Learn more about the study.

FDA leadership changes could shift regulatory priorities. Learn which policies, from accelerated approval to AI guidance, face potential revisions.

A new clinical trial shows that a novel liquid supplement significantly reduces LDL cholesterol, offering a promising new tool for heart health management.

Hansoh Pharmaceutical’s HS-20093 met primary endpoints in the ARTEMIS-008 trial, showing significant survival benefits for patients with SCLC.

AstraZeneca’s latest clinical setback forces investors to rethink pharma valuation. Learn how R&D risks and pipeline diversity shape long-term stock value.

A new Phase 2 trial shows a promising Shigella vaccine induces a strong immune response, potentially offering a breakthrough against antibiotic-resistant bacteria.

Amgen is defending its vasculitis drug Tavneos amid global regulatory concerns over safety. Learn about the potential impact on clinical guidelines.